Skip to main content
Avicanna Inc. logo

Avicanna Inc. — Investor Relations & Filings

Ticker · AVCN ISIN · CA05368K1003 LEI · 254900AUQ4URGWO3FN90 TSX Manufacturing
Open in API
Filings indexed 484 across all filing types
Latest filing 2020-09-21 Capital/Financing Update
Country CA Canada
Listing TSX AVCN

About Avicanna Inc.

https://www.avicanna.com/

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based, cannabinoid-based products for the global medical and pharmaceutical markets. The company operates through four commercial pillars: Medical Cannabis Products (RHO Phyto™), a Medical Cannabis Care Platform (MyMedi.ca), a Pharmaceutical Pipeline, and Active Pharmaceutical Ingredients (Aureus Santa Marta™). Avicanna leverages an industry-leading scientific platform, including R&D collaborations with academic institutions and a robust IP portfolio, resulting in over 50 proprietary commercialized SKUs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a press release announcing the commercial availability of Avicanna's RHO Phyto Rapid Act Sprays nationwide in Canada. It focuses on product launch details, partnerships, manufacturing standards, and forward-looking statements about future product launches and company activities. There is no financial data, regulatory filing, or detailed report content such as financial statements or management analysis. The document is promotional and informational in nature, typical of a Capital/Financing Update or product launch announcement. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. Given the content and context, the best fitting category is Capital/Financing Update (CAP), as it relates to company product commercialization and market availability updates.
2020-09-21 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Avicanna's subsidiary has obtained certification and authorization for the compounding and sale of pharmaceutical cannabinoid products in Colombia. It discusses the company's business model, product lines, and future plans but does not contain any financial statements, detailed financial performance data, or regulatory filings. It is an announcement of a business development rather than a financial report or regulatory filing. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a general regulatory announcement or business update, which falls under Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other specific categories.
2020-09-14 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Avicanna's subsidiary has obtained certification and authorization for the compounding and sale of pharmaceutical cannabinoid products in Colombia. It discusses the company's business model, product lines, and market strategy but does not contain any financial statements, regulatory filings, or detailed financial data. There is no indication that this is an earnings release, annual or interim report, or any other formal regulatory filing. The content is primarily a corporate announcement about a business development and regulatory approval. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other specific categories.
2020-09-14 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Avicanna has amended and refiled its interim financial statements for the period ended June 30, 2020. It specifies that the amendment was made at the request of the Ontario Securities Commission to include comparative financial information that was previously omitted. The document contains no actual financial statements or substantive financial data itself, but rather discusses the filing and amendment of the interim financial statements. It also includes business updates about exports and regulatory approvals but does not present a full interim report. Given the document length (8596 characters) and content, it is not the interim report itself but an announcement about the amended interim financial statements filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such announcements and compliance-related filings that do not contain the full report or detailed financial data.
2020-09-04 English
52-109F2R - Certification of refiled interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F2R Certification of Refiled Interim Filings for the interim period ended June 30, 2020. It is a certification by the CEO regarding the review, fair presentation, and controls related to the interim financial report and MD&A. The document does not contain the actual interim financial statements or substantive financial data but is a certification letter confirming the accuracy and completeness of the interim filings. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3493 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2020-09-04 English
52-109F2R - Certification of refiled interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109F2R Certification of Refiled Interim Filings by the CFO of Avicanna Inc. It certifies the accuracy and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2020. The document is primarily an officer certification letter confirming the integrity of the interim filings, referencing National Instrument 52-109. It does not contain actual financial statements or substantive financial data itself, but rather attests to the filings. According to the CERTIFICATION RULE, such documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) itself.
2020-09-04 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.